Davita-St. Luke's Allentown Dialysis is a medicare approved dialysis facility center in Allentown, Pennsylvania and it has 4 dialysis stations. It is located in Lehigh county at 1901 Hamilton St., Allentown, PA, 18104. You can reach out to the office of Davita-St. Luke's Allentown Dialysis at (610) 435-2590. This dialysis clinic is managed and/or owned by Davita. Davita-St. Luke's Allentown Dialysis has the following ownership type - Profit. It was first certified by medicare in September, 2013. The medicare id for this facility is 392818 and it accepts patients under medicare ESRD program.
| Name | Davita-St. Luke's Allentown Dialysis |
|---|---|
| Location | 1901 Hamilton St., Allentown, Pennsylvania |
| No. of Dialysis Stations | 4 |
| Medicare ID | 392818 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 1901 Hamilton St., Allentown, Pennsylvania, 18104 | |
| (610) 435-2590 | |
News Archive
As states open insurance marketplaces amid uncertainty about whether they're a solution for health care, Vermont is eyeing a bigger goal, one that more fully embraces a government-funded model. The state has a planned 2017 launch of the nation's first universal health care system, a sort of modified Medicare-for-all that has long been a dream for many liberals (Gram, 10/26).
Researchers at Mayo Clinic, with their national and international collaborators, have discovered how a class of agents now in testing to treat Alzheimer's disease work, and say they may open up an avenue of drug discovery for this disease and others.
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) vaccine company, will collaborate with the Gynecologic Oncology Group (GOG), a collaborative research group of the National Cancer Institute (NCI), in a multicenter, Phase II clinical trial of the Company's lead drug candidate, ADXS11-001 in the treatment of advanced cervix cancer in women who have failed prior cytotoxic therapy.
Researchers have demonstrated a technique that has the potential to reduce the toxicity of vaccines and to make smaller doses more effective, according to a study published in PLoS Pathogens.
Decision Resources, Inc., a research and advisory firm focusing on pharmaceutical and healthcare issues, finds that first-in-class targeted biologics will enter the malignant melanoma market during the next five years.
› Verified 4 days ago
| NPI Number | 1790111060 |
| Organization Name | St Lukes Allentown Dialysis |
| Doing Business As | Etowah Dialysis Llc |
| Address | 1901 Hamilton St Allentown, Pennsylvania, 18104 |
| Phone Number | (610) 435-2590 |
News Archive
As states open insurance marketplaces amid uncertainty about whether they're a solution for health care, Vermont is eyeing a bigger goal, one that more fully embraces a government-funded model. The state has a planned 2017 launch of the nation's first universal health care system, a sort of modified Medicare-for-all that has long been a dream for many liberals (Gram, 10/26).
Researchers at Mayo Clinic, with their national and international collaborators, have discovered how a class of agents now in testing to treat Alzheimer's disease work, and say they may open up an avenue of drug discovery for this disease and others.
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) vaccine company, will collaborate with the Gynecologic Oncology Group (GOG), a collaborative research group of the National Cancer Institute (NCI), in a multicenter, Phase II clinical trial of the Company's lead drug candidate, ADXS11-001 in the treatment of advanced cervix cancer in women who have failed prior cytotoxic therapy.
Researchers have demonstrated a technique that has the potential to reduce the toxicity of vaccines and to make smaller doses more effective, according to a study published in PLoS Pathogens.
Decision Resources, Inc., a research and advisory firm focusing on pharmaceutical and healthcare issues, finds that first-in-class targeted biologics will enter the malignant melanoma market during the next five years.
› Verified 4 days ago
| Dialysis patients with Hemoglobin data | 22 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 18 |
News Archive
As states open insurance marketplaces amid uncertainty about whether they're a solution for health care, Vermont is eyeing a bigger goal, one that more fully embraces a government-funded model. The state has a planned 2017 launch of the nation's first universal health care system, a sort of modified Medicare-for-all that has long been a dream for many liberals (Gram, 10/26).
Researchers at Mayo Clinic, with their national and international collaborators, have discovered how a class of agents now in testing to treat Alzheimer's disease work, and say they may open up an avenue of drug discovery for this disease and others.
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) vaccine company, will collaborate with the Gynecologic Oncology Group (GOG), a collaborative research group of the National Cancer Institute (NCI), in a multicenter, Phase II clinical trial of the Company's lead drug candidate, ADXS11-001 in the treatment of advanced cervix cancer in women who have failed prior cytotoxic therapy.
Researchers have demonstrated a technique that has the potential to reduce the toxicity of vaccines and to make smaller doses more effective, according to a study published in PLoS Pathogens.
Decision Resources, Inc., a research and advisory firm focusing on pharmaceutical and healthcare issues, finds that first-in-class targeted biologics will enter the malignant melanoma market during the next five years.
› Verified 4 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 65 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 479 |
| Percentage of adult patients getting regular hemodialysis at the center | 95 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
As states open insurance marketplaces amid uncertainty about whether they're a solution for health care, Vermont is eyeing a bigger goal, one that more fully embraces a government-funded model. The state has a planned 2017 launch of the nation's first universal health care system, a sort of modified Medicare-for-all that has long been a dream for many liberals (Gram, 10/26).
Researchers at Mayo Clinic, with their national and international collaborators, have discovered how a class of agents now in testing to treat Alzheimer's disease work, and say they may open up an avenue of drug discovery for this disease and others.
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) vaccine company, will collaborate with the Gynecologic Oncology Group (GOG), a collaborative research group of the National Cancer Institute (NCI), in a multicenter, Phase II clinical trial of the Company's lead drug candidate, ADXS11-001 in the treatment of advanced cervix cancer in women who have failed prior cytotoxic therapy.
Researchers have demonstrated a technique that has the potential to reduce the toxicity of vaccines and to make smaller doses more effective, according to a study published in PLoS Pathogens.
Decision Resources, Inc., a research and advisory firm focusing on pharmaceutical and healthcare issues, finds that first-in-class targeted biologics will enter the malignant melanoma market during the next five years.
› Verified 4 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Davita-St. Luke's Allentown Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 66 |
| Hypercalcemia patient months | 485 |
| Patients with Serumphosphor | 73 |
| Patients with Serumphosphor less than 3.5 mg/dL | 11 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 24 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 30 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 19 |
| Patients with Serumphosphor greater than 7 mg/dL | 16 |
News Archive
As states open insurance marketplaces amid uncertainty about whether they're a solution for health care, Vermont is eyeing a bigger goal, one that more fully embraces a government-funded model. The state has a planned 2017 launch of the nation's first universal health care system, a sort of modified Medicare-for-all that has long been a dream for many liberals (Gram, 10/26).
Researchers at Mayo Clinic, with their national and international collaborators, have discovered how a class of agents now in testing to treat Alzheimer's disease work, and say they may open up an avenue of drug discovery for this disease and others.
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) vaccine company, will collaborate with the Gynecologic Oncology Group (GOG), a collaborative research group of the National Cancer Institute (NCI), in a multicenter, Phase II clinical trial of the Company's lead drug candidate, ADXS11-001 in the treatment of advanced cervix cancer in women who have failed prior cytotoxic therapy.
Researchers have demonstrated a technique that has the potential to reduce the toxicity of vaccines and to make smaller doses more effective, according to a study published in PLoS Pathogens.
Decision Resources, Inc., a research and advisory firm focusing on pharmaceutical and healthcare issues, finds that first-in-class targeted biologics will enter the malignant melanoma market during the next five years.
› Verified 4 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 57 |
| Patient months included in arterial venous fistula and catheter summaries | 328 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 73 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 8 |
News Archive
As states open insurance marketplaces amid uncertainty about whether they're a solution for health care, Vermont is eyeing a bigger goal, one that more fully embraces a government-funded model. The state has a planned 2017 launch of the nation's first universal health care system, a sort of modified Medicare-for-all that has long been a dream for many liberals (Gram, 10/26).
Researchers at Mayo Clinic, with their national and international collaborators, have discovered how a class of agents now in testing to treat Alzheimer's disease work, and say they may open up an avenue of drug discovery for this disease and others.
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) vaccine company, will collaborate with the Gynecologic Oncology Group (GOG), a collaborative research group of the National Cancer Institute (NCI), in a multicenter, Phase II clinical trial of the Company's lead drug candidate, ADXS11-001 in the treatment of advanced cervix cancer in women who have failed prior cytotoxic therapy.
Researchers have demonstrated a technique that has the potential to reduce the toxicity of vaccines and to make smaller doses more effective, according to a study published in PLoS Pathogens.
Decision Resources, Inc., a research and advisory firm focusing on pharmaceutical and healthcare issues, finds that first-in-class targeted biologics will enter the malignant melanoma market during the next five years.
› Verified 4 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 45 |
| Hospitalization Rate in facility | 236.4 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 415.7 |
| Hospitalization Rate: Lower Confidence Limit | 140.5 |
News Archive
As states open insurance marketplaces amid uncertainty about whether they're a solution for health care, Vermont is eyeing a bigger goal, one that more fully embraces a government-funded model. The state has a planned 2017 launch of the nation's first universal health care system, a sort of modified Medicare-for-all that has long been a dream for many liberals (Gram, 10/26).
Researchers at Mayo Clinic, with their national and international collaborators, have discovered how a class of agents now in testing to treat Alzheimer's disease work, and say they may open up an avenue of drug discovery for this disease and others.
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) vaccine company, will collaborate with the Gynecologic Oncology Group (GOG), a collaborative research group of the National Cancer Institute (NCI), in a multicenter, Phase II clinical trial of the Company's lead drug candidate, ADXS11-001 in the treatment of advanced cervix cancer in women who have failed prior cytotoxic therapy.
Researchers have demonstrated a technique that has the potential to reduce the toxicity of vaccines and to make smaller doses more effective, according to a study published in PLoS Pathogens.
Decision Resources, Inc., a research and advisory firm focusing on pharmaceutical and healthcare issues, finds that first-in-class targeted biologics will enter the malignant melanoma market during the next five years.
› Verified 4 days ago
The rate of readmission show you whether patients who were being treated regularly at Davita-St. Luke's Allentown Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 33.8 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 46.7 |
| Readmission Rate: Lower Confidence Limit | 22.7 |
News Archive
As states open insurance marketplaces amid uncertainty about whether they're a solution for health care, Vermont is eyeing a bigger goal, one that more fully embraces a government-funded model. The state has a planned 2017 launch of the nation's first universal health care system, a sort of modified Medicare-for-all that has long been a dream for many liberals (Gram, 10/26).
Researchers at Mayo Clinic, with their national and international collaborators, have discovered how a class of agents now in testing to treat Alzheimer's disease work, and say they may open up an avenue of drug discovery for this disease and others.
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) vaccine company, will collaborate with the Gynecologic Oncology Group (GOG), a collaborative research group of the National Cancer Institute (NCI), in a multicenter, Phase II clinical trial of the Company's lead drug candidate, ADXS11-001 in the treatment of advanced cervix cancer in women who have failed prior cytotoxic therapy.
Researchers have demonstrated a technique that has the potential to reduce the toxicity of vaccines and to make smaller doses more effective, according to a study published in PLoS Pathogens.
Decision Resources, Inc., a research and advisory firm focusing on pharmaceutical and healthcare issues, finds that first-in-class targeted biologics will enter the malignant melanoma market during the next five years.
› Verified 4 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Davita-St. Luke's Allentown Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .88 (As Expected) |
| SIR: Upper Confidence Limit | 2.9 |
| SIR: Lower Confidence Limit | .15 |
News Archive
As states open insurance marketplaces amid uncertainty about whether they're a solution for health care, Vermont is eyeing a bigger goal, one that more fully embraces a government-funded model. The state has a planned 2017 launch of the nation's first universal health care system, a sort of modified Medicare-for-all that has long been a dream for many liberals (Gram, 10/26).
Researchers at Mayo Clinic, with their national and international collaborators, have discovered how a class of agents now in testing to treat Alzheimer's disease work, and say they may open up an avenue of drug discovery for this disease and others.
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) vaccine company, will collaborate with the Gynecologic Oncology Group (GOG), a collaborative research group of the National Cancer Institute (NCI), in a multicenter, Phase II clinical trial of the Company's lead drug candidate, ADXS11-001 in the treatment of advanced cervix cancer in women who have failed prior cytotoxic therapy.
Researchers have demonstrated a technique that has the potential to reduce the toxicity of vaccines and to make smaller doses more effective, according to a study published in PLoS Pathogens.
Decision Resources, Inc., a research and advisory firm focusing on pharmaceutical and healthcare issues, finds that first-in-class targeted biologics will enter the malignant melanoma market during the next five years.
› Verified 4 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Davita-St. Luke's Allentown Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 38 |
| Transfusion Rate in facility | 20.5 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 119.8 |
| Transfusion Rate: Lower Confidence Limit | 4.3 |
News Archive
As states open insurance marketplaces amid uncertainty about whether they're a solution for health care, Vermont is eyeing a bigger goal, one that more fully embraces a government-funded model. The state has a planned 2017 launch of the nation's first universal health care system, a sort of modified Medicare-for-all that has long been a dream for many liberals (Gram, 10/26).
Researchers at Mayo Clinic, with their national and international collaborators, have discovered how a class of agents now in testing to treat Alzheimer's disease work, and say they may open up an avenue of drug discovery for this disease and others.
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) vaccine company, will collaborate with the Gynecologic Oncology Group (GOG), a collaborative research group of the National Cancer Institute (NCI), in a multicenter, Phase II clinical trial of the Company's lead drug candidate, ADXS11-001 in the treatment of advanced cervix cancer in women who have failed prior cytotoxic therapy.
Researchers have demonstrated a technique that has the potential to reduce the toxicity of vaccines and to make smaller doses more effective, according to a study published in PLoS Pathogens.
Decision Resources, Inc., a research and advisory firm focusing on pharmaceutical and healthcare issues, finds that first-in-class targeted biologics will enter the malignant melanoma market during the next five years.
› Verified 4 days ago
The rate of mortality show you whether patients who were being treated regularly at Davita-St. Luke's Allentown Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 120 |
| Mortality Rate in facility | 14.4 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 27.4 |
| Mortality Rate: Lower Confidence Limit | 6.6 |
News Archive
As states open insurance marketplaces amid uncertainty about whether they're a solution for health care, Vermont is eyeing a bigger goal, one that more fully embraces a government-funded model. The state has a planned 2017 launch of the nation's first universal health care system, a sort of modified Medicare-for-all that has long been a dream for many liberals (Gram, 10/26).
Researchers at Mayo Clinic, with their national and international collaborators, have discovered how a class of agents now in testing to treat Alzheimer's disease work, and say they may open up an avenue of drug discovery for this disease and others.
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) vaccine company, will collaborate with the Gynecologic Oncology Group (GOG), a collaborative research group of the National Cancer Institute (NCI), in a multicenter, Phase II clinical trial of the Company's lead drug candidate, ADXS11-001 in the treatment of advanced cervix cancer in women who have failed prior cytotoxic therapy.
Researchers have demonstrated a technique that has the potential to reduce the toxicity of vaccines and to make smaller doses more effective, according to a study published in PLoS Pathogens.
Decision Resources, Inc., a research and advisory firm focusing on pharmaceutical and healthcare issues, finds that first-in-class targeted biologics will enter the malignant melanoma market during the next five years.
› Verified 4 days ago
Fresenius Medical Care Allentown Location: 3136 Hamilton Boulevard, Allentown, Pennsylvania, 18103 Phone: (610) 435-6718 |
Fresenius Medical Care South Allentown Location: 2820 Mitchell Avenue, Allentown, Pennsylvania, 18103 Phone: (610) 797-7655 |
Davita-St. Luke's Allentown Dialysis Location: 1901 Hamilton St., Allentown, Pennsylvania, 18104 Phone: (610) 435-2590 |
Fresenius Medical Care - Fogelsville Location: 7310 Tilghman Street, Allentown, Pennsylvania, 18106 Phone: (610) 395-1980 |
Etowah Dialysis, Llc Location: 1901 Hamilton Street, Allentown, Pennsylvania, 18104 Phone: (610) 776-1479 |
News Archive
As states open insurance marketplaces amid uncertainty about whether they're a solution for health care, Vermont is eyeing a bigger goal, one that more fully embraces a government-funded model. The state has a planned 2017 launch of the nation's first universal health care system, a sort of modified Medicare-for-all that has long been a dream for many liberals (Gram, 10/26).
Researchers at Mayo Clinic, with their national and international collaborators, have discovered how a class of agents now in testing to treat Alzheimer's disease work, and say they may open up an avenue of drug discovery for this disease and others.
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) vaccine company, will collaborate with the Gynecologic Oncology Group (GOG), a collaborative research group of the National Cancer Institute (NCI), in a multicenter, Phase II clinical trial of the Company's lead drug candidate, ADXS11-001 in the treatment of advanced cervix cancer in women who have failed prior cytotoxic therapy.
Researchers have demonstrated a technique that has the potential to reduce the toxicity of vaccines and to make smaller doses more effective, according to a study published in PLoS Pathogens.
Decision Resources, Inc., a research and advisory firm focusing on pharmaceutical and healthcare issues, finds that first-in-class targeted biologics will enter the malignant melanoma market during the next five years.
› Verified 4 days ago